following an abbreviated submission:
cholecalciferol oral solution (InVita D3®) is accepted for use within NHS Scotland.
Indication under review: the prevention and treatment of vitamin D deficiency.
As an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.
The therapeutic use and safety profile of cholecalciferol as a treatment for vitamin D deficiency and as an adjunctive treatment in osteoporosis is well established. InVita D3® provides a higher strength preparation than some other licensed vitamin D preparations and is licensed for use in both children and adults. At equivalent doses, it is a similar cost to other vitamin D preparations. InVitaD3® is listed in the British National Formulary for Children 2014-2015.
Download detailed advice54KB (PDF)
- Medicine name:
- cholecalciferol 25,000 international units oral solution (InVita D3)
- SMC ID:
- the prevention and treatment of vitamin D deficiency.
- Pharmaceutical company
- Consilient Health Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Date advice published
- 08 December 2014